Abstract
The first generation of in silico hERG models have focused on key driving forces for hERG/ligand binding: basicity and lipophilicity. While reducing basicity and lipophilicity are typically the first line approaches to eliminating hERG blocking activity, in many programs these are not feasible approaches because basicity and lipophilicity are frequently necessary for achieving good pharmacokinetics or primary target binding. Thus for the second, generation of in silico hERG models, a focus on understanding the more subtle aspects of hERG binding is necessary. Thus, the focus of this review is on extracting ideas, either qualitative or quantitative, from the various modeling efforts as to how hERG activity might be eliminated or diminished beyond simply reducing basicity and lipophilicity. In addition, several areas where key questions around hERG binding have not been adequately addressed by in silico work are highlighted.
Current Computer-Aided Drug Design
Title: In Silico hERG Modeling: Challenges and Progress
Volume: 5 Issue: 2
Author(s): David J. Diller
Affiliation:
Abstract: The first generation of in silico hERG models have focused on key driving forces for hERG/ligand binding: basicity and lipophilicity. While reducing basicity and lipophilicity are typically the first line approaches to eliminating hERG blocking activity, in many programs these are not feasible approaches because basicity and lipophilicity are frequently necessary for achieving good pharmacokinetics or primary target binding. Thus for the second, generation of in silico hERG models, a focus on understanding the more subtle aspects of hERG binding is necessary. Thus, the focus of this review is on extracting ideas, either qualitative or quantitative, from the various modeling efforts as to how hERG activity might be eliminated or diminished beyond simply reducing basicity and lipophilicity. In addition, several areas where key questions around hERG binding have not been adequately addressed by in silico work are highlighted.
Export Options
About this article
Cite this article as:
Diller J. David, In Silico hERG Modeling: Challenges and Progress, Current Computer-Aided Drug Design 2009; 5 (2) . https://dx.doi.org/10.2174/157340909788451928
DOI https://dx.doi.org/10.2174/157340909788451928 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Vinyl Sulfone Containing Parasitic Cysteinyl Protease Inhibitors
Current Bioactive Compounds Subject Index To Volume 2
Current Hypertension Reviews Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine Metabolomics Reveals Hyperlipidemic Biomarkers and Antihyperlipidemic Effect of Poria cocos
Current Metabolomics Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis: An Uncommon Yet Important Complication
Current Rheumatology Reviews Identification of Defective CD36 as a Quantitative Trait Locus for Cardiovascular Risk Factor Clustering in the Spontaneously Hypertensive Rat
Current Genomics Arterial Stiffness and Hypertension: A Review of Mechanism and Clinical Relevance
Current Hypertension Reviews Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Quality Assessment of Wheat Bread with Microbial Transglutaminase Supplemented with Hull-Less Barley Flour
Current Nutrition & Food Science Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry The Role of Dietary Fats in Hypertension, Obesity and Insulin Resistance: A Comparative Study of Animals and Humans in Fetal and Adult Life
Current Nutrition & Food Science Flavonoids, Vascular Function and Cardiovascular Protection
Current Pharmaceutical Design Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Review of Rational Approaches to the Treatment of Pain Management-Role forOpioids Therapies
Current Drug Therapy Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry On the Analysis of Fingertip Photoplethysmogram Signals
Current Cardiology Reviews